INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) is a distressing side effect that affects many patients undergoing emetogenic chemotherapy, despite the use of antiemetic medications. The purpose of this trial was to evaluate the efficacy and safety of gabapentin for the prevention of CINV during the first cycle of treatment in patients receiving moderately or highly emetogenic chemotherapy. METHODS:Eighty chemotherapy-naive patients, scheduled to receive moderately and highlyemetogenic chemotherapy, were enrolled in this randomised, double-blind, placebo-controlled clinical trial. All patients received intravenous ondansetron 8 mg, dexamethasone 10 mg and ranitidine 50 mg before chemotherapy on day 1 and oral dexamethasone 4 mg twice a day on days 2 and 3. Patients were randomly assigned to take gabapentin 300 mg or placebo on the following schedule: 5 and 4 days before chemotherapy once daily, 3 and 2 days before chemotherapy twice daily, 1 day before to 5 days after chemotherapy thrice daily. The primary endpoint was complete overall protection from both vomiting and nausea over the course of the entire study (day 1 through day 5), and complete protection during the delayed period (24-120 h after chemotherapy). RESULTS: The proportion of patients achieving complete response improved from 40% to 62.5%, (p = 0.04) when comparing the control group and the gabapentin group, respectively. In the subset of patients who achieved complete control in the acute phase, the percentage of patients who achieved delayed complete control was higher in the gabapentin group (89.3 × 60.7%, p = 0.01). Adverse events did not significantly differ between study arms. CONCLUSIONS:Gabapentin is a low-cost strategy to improve complete control of CINV, specially delayed CINV control.
RCT Entities:
INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) is a distressing side effect that affects many patients undergoing emetogenic chemotherapy, despite the use of antiemetic medications. The purpose of this trial was to evaluate the efficacy and safety of gabapentin for the prevention of CINV during the first cycle of treatment in patients receiving moderately or highly emetogenic chemotherapy. METHODS: Eighty chemotherapy-naive patients, scheduled to receive moderately and highly emetogenic chemotherapy, were enrolled in this randomised, double-blind, placebo-controlled clinical trial. All patients received intravenous ondansetron 8 mg, dexamethasone 10 mg and ranitidine 50 mg before chemotherapy on day 1 and oral dexamethasone 4 mg twice a day on days 2 and 3. Patients were randomly assigned to take gabapentin 300 mg or placebo on the following schedule: 5 and 4 days before chemotherapy once daily, 3 and 2 days before chemotherapy twice daily, 1 day before to 5 days after chemotherapy thrice daily. The primary endpoint was complete overall protection from both vomiting and nausea over the course of the entire study (day 1 through day 5), and complete protection during the delayed period (24-120 h after chemotherapy). RESULTS: The proportion of patients achieving complete response improved from 40% to 62.5%, (p = 0.04) when comparing the control group and the gabapentin group, respectively. In the subset of patients who achieved complete control in the acute phase, the percentage of patients who achieved delayed complete control was higher in the gabapentin group (89.3 × 60.7%, p = 0.01). Adverse events did not significantly differ between study arms. CONCLUSIONS:Gabapentin is a low-cost strategy to improve complete control of CINV, specially delayed CINV control.
Authors: R Gralla; M Lichinitser; S Van Der Vegt; H Sleeboom; J Mezger; C Peschel; G Tonini; R Labianca; A Macciocchi; M Aapro Journal: Ann Oncol Date: 2003-10 Impact factor: 32.976
Authors: Arash Naeim; Sydney M Dy; Karl A Lorenz; Homayoon Sanati; Anne Walling; Steven M Asch Journal: J Clin Oncol Date: 2008-08-10 Impact factor: 44.544
Authors: P J Hesketh; W H Harvey; W G Harker; T M Beck; T Ryan; L J Bricker; J A Kish; W K Murphy; J D Hainsworth; B Haley Journal: J Clin Oncol Date: 1994-03 Impact factor: 44.544
Authors: F Roila; M Tonato; F Cognetti; E Cortesi; G Favalli; M Marangolo; D Amadori; M A Bella; V Gramazio; D Donati Journal: J Clin Oncol Date: 1991-04 Impact factor: 44.544
Authors: Thaiana Aragão Santana; Damila Cristina Trufelli; Leandro Luongo de Matos; Felipe Melo Cruz; Auro Del Giglio Journal: Support Care Cancer Date: 2014-08-22 Impact factor: 3.603
Authors: Catalina Hernandez Torres; Sasha Mazzarello; Terry Ng; George Dranitsaris; Brian Hutton; Stephanie Smith; Amy Munro; Carmel Jacobs; Mark Clemons Journal: Support Care Cancer Date: 2015-06-25 Impact factor: 3.603
Authors: Debra L Barton; Gita Thanarajasingam; Jeff A Sloan; Brent Diekmann; Jyotsna Fuloria; Lisa A Kottschade; Alan P Lyss; Anthony J Jaslowski; Miroslaw A Mazurczak; Scott C Blair; Shelby Terstriep; Charles L Loprinzi Journal: Cancer Date: 2014-07-09 Impact factor: 6.860
Authors: J Flank; J Sparavalo; H Vol; L Hagen; R Stuhler; D Chong; S Courtney; J J Doyle; A Gassas; T Schechter; L L Dupuis Journal: Bone Marrow Transplant Date: 2017-06-05 Impact factor: 5.483
Authors: Michelle C Janelsins; Mohamedtaki A Tejani; Charles Kamen; Anita R Peoples; Karen M Mustian; Gary R Morrow Journal: Expert Opin Pharmacother Date: 2013-04 Impact factor: 3.889
Authors: Shivani Shinde; Pamela Gordon; Prashant Sharma; James Gross; Mellar P Davis Journal: Support Care Cancer Date: 2014-08-29 Impact factor: 3.603